[go: up one dir, main page]

AU5098493A - Cd40 ligand, anti cd40 antibodies, and soluble cd40 - Google Patents

Cd40 ligand, anti cd40 antibodies, and soluble cd40

Info

Publication number
AU5098493A
AU5098493A AU50984/93A AU5098493A AU5098493A AU 5098493 A AU5098493 A AU 5098493A AU 50984/93 A AU50984/93 A AU 50984/93A AU 5098493 A AU5098493 A AU 5098493A AU 5098493 A AU5098493 A AU 5098493A
Authority
AU
Australia
Prior art keywords
ligand
antibodies
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50984/93A
Inventor
Andrew W Heath
Maureen Howard
Lewis L. Lanier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU5098493A publication Critical patent/AU5098493A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU50984/93A 1992-08-21 1993-08-19 Cd40 ligand, anti cd40 antibodies, and soluble cd40 Abandoned AU5098493A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US934371 1978-08-16
US93437192A 1992-08-21 1992-08-21
PCT/US1993/007673 WO1994004570A1 (en) 1992-08-21 1993-08-19 Cd40 ligand, anti cd40 antibodies, and soluble cd40

Publications (1)

Publication Number Publication Date
AU5098493A true AU5098493A (en) 1994-03-15

Family

ID=25465448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50984/93A Abandoned AU5098493A (en) 1992-08-21 1993-08-19 Cd40 ligand, anti cd40 antibodies, and soluble cd40

Country Status (2)

Country Link
AU (1) AU5098493A (en)
WO (1) WO1994004570A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
AU677788B2 (en) * 1992-09-04 1997-05-08 Bristol-Myers Squibb Company Soluble ligands for CD40

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
DE69422523T2 (en) 1993-09-02 2000-10-12 Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton ANTI-GP39 ANTIBODIES AND THEIR USE
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5817516A (en) 1994-04-28 1998-10-06 Boehringer Ingelheim Pharmaceuticals, Inc. Methods for proliferating and differentiating B cells with high density membrane CD40 ligand
CA2213798C (en) * 1995-03-01 2001-02-06 Immunex Corporation Method for stimulating an immune response
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6197584B1 (en) * 1998-05-01 2001-03-06 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 expression
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001078769A2 (en) * 2000-04-12 2001-10-25 University Of South Florida Regulation of systemic immune responses utilizing soluble cd40
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
EP1326896B1 (en) 2000-10-02 2010-11-24 Novartis Vaccines and Diagnostics, Inc. Human anti-cd40 antibodies
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP1791563A4 (en) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154 antibodies
US10174121B2 (en) 2015-05-29 2019-01-08 Abbvie, Inc. Anti-CD40 antibodies
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
CN119823269A (en) * 2024-12-10 2025-04-15 上海交通大学医学院附属瑞金医院 Epitope peptide of CD40 ligand, antibody and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434879A1 (en) * 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
DK0667901T4 (en) * 1991-10-25 2008-11-10 Immunex Corp Hitherto unknown cytokine
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677788B2 (en) * 1992-09-04 1997-05-08 Bristol-Myers Squibb Company Soluble ligands for CD40
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide

Also Published As

Publication number Publication date
WO1994004570A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
AU5098493A (en) Cd40 ligand, anti cd40 antibodies, and soluble cd40
USH1157H (en) Filter
AU3570193A (en) Altered antibodies, products and processes relating thereto
AU1353997A (en) Subtype-selective nmda receptor ligands and the use thereof
AU3694189A (en) Methods, compositions, and systems for ligand extraction
AU1687795A (en) B7-1-specific ligands, and their use for the induction of t cell anergy
AU1463997A (en) Subtype-selective nmda receptor ligands and the use thereof
AU3780393A (en) Quinobenzoxazine, quinobenzothiazine, and pyrido-acridine antineoplastic agents
AU694955B2 (en) Pyridazinone derivatives and processes for preparing the same
AU7634694A (en) Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
AU2402992A (en) File
AU5581594A (en) Cigarette and process for preparing the cigarette
AU5922694A (en) 2-amino-4-quinolyl-dihydropyridines, processes for their preparation, and their use
AU5680594A (en) Pad, tape and forming methods
AU7571194A (en) Azotobacterin and the method for preparing the same
AU4837693A (en) Improved method for preparing soluble glucans
AU5873994A (en) Immune response modulator complex, and uses thereof
HRP931016A2 (en) Thienothiazin derivatives, process for the preparation and application thereof
AU4175393A (en) Filter
AU3266295A (en) Security container
HK1010795B (en) Security container
AU3544293A (en) Improved cut-off means
EP0603840A3 (en) Pivot.
AU4674596A (en) Complexes, processes for their preparation and their use
EP0621866A4 (en) Process for preparing 3-acylestratrienes and acylbenzenes.